ClinicalTrials.gg
CompletedNCT04183790Updated May 18, 2025Results posted

Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA TC Combination Therapy in Participants With Cystic Fibrosis Who Are 6 Years of Age and Older

A Phase 3 interventional study of ELX/TEZ/IVA and IVA in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 21 sites in 5 countries. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2025-05-18.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
64
Allocation
Not applicable
Ages
6 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing elexacaftor in Cystic Fibrosis — 2 open to participants now, 5 under way, 2 of them phase 3. elexacaftor · Cystic Fibrosis.

Enrollment
21st of 23
64 · median 120
Started
2020
with 4 others
Phase 3
19 of 23
none open now
Registered
8th of 23
by date
Lead sponsor
20 of 23
Vertex Pharmaceuticals Incorporated

Among the 23 studies testing elexacaftor in Cystic Fibrosis, this one is the 21st largest by enrollment, is one of 5 that started in 2020, is one of 19 in phase 3, and was the 8th registered.

Cystic Fibrosis

1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

2 of the 23 studies testing elexacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About elexacaftor

elexacaftor: first FDA approval 2019 (TRIKAFTA (COPACKAGED)), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.

This study: 6 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing elexacaftor in Cystic Fibrosis, or all of them as a file.
02

Study summary

The study evaluates the long-term safety, tolerability, efficacy, and pharmacodynamics of elexacaftor (ELX, VX-445) in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in participants with cystic fibrosis (CF).

03

Conditions studied

  • Cystic Fibrosis

Browse trials for

04

Who can participate

Ages eligible
6 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Completed study drug treatment in parent study (VX18-445-106 Part B, NCT03691779), or had study drug interruption(s) in parent study but completed study visits up to the last scheduled visit of the Treatment Period in the parent study

Key Exclusion Criteria:

  • History of study drug intolerance in parent study

Other protocol defined Inclusion/Exclusion criteria may apply.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    ELX/TEZ/IVA

    Participants greater than or equal to (≥) 6 years and less than (\<) 12 years of age and weighing \<30 kilograms (kg) received ELX (elexacaftor) 100 milligram (mg) once daily (qd) /TEZ (tezacaftor) 50 mg qd/IVA (ivacaftor) 75 mg every 12 hours (q12h) and those weighing (≥) 30 kg received ELX 200 mg qd/TEZ 100 mg qd/IVA 150 mg in the treatment period for up to 192 weeks. Participants ≥12 years of age received ELX 200 mg qd/ TEZ 100 mg qd/IVA 150 mg q12h in the treatment period for up to 192 weeks.

    Drug: ELX/TEZ/IVA · Drug: IVA

Interventions

  • DrugELX/TEZ/IVA

    Drug pages: Elexacaftor · Tezacaftor · Ivacaftor

    Fixed-dose combination (FDC) tablet for oral administration

    Also known as: VX-445/VX-661/VX-770, elexacaftor/tezacaftor/ivacaftor

  • DrugIVA

    Mono tablet for oral administration.

    Also known as: VX-770, ivacaftor

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability as Assessed by Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Time frame: From Baseline up to Week 196

Secondary outcomes

  1. Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)

    FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

    Time frame: From Baseline up to Week 192

  2. Absolute Change in Sweat Chloride (SwCl)

    Sweat samples were collected using an approved collection device.

    Time frame: From Baseline up to Week 192

  3. Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score

    The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.

    Time frame: From Baseline up to Week 192

  4. Absolute Change in Body Mass Index (BMI)

    BMI was defined as weight in kg divided by squared height in meters (m\^2).

    Time frame: From Baseline up to Week 192

  5. Absolute Change in BMI-for-age Z-score

    BMI was defined as weight in kg divided by squared height in meters (m\^2). The z-score is a statistical measure to describe whether a mean was above or below the standard. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean.

    Time frame: From Baseline up to Week 192

  6. Number of Participants With Pulmonary Exacerbations (PEx) for 106/107

    Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms.

    Time frame: From Baseline up to Week 192

  7. Number of CF-related Hospitalizations for 106/107

    The total number of CF related hospitalization (Planned + Unplanned) events across all participants were reported.

    Time frame: From Baseline up to Week 192

  8. Absolute Change in Lung Clearance Index 2.5 (LCI 2.5)

    The LCI2.5 index is the number of lung turnovers required to reduce the end tidal inert gas concentration to 1/40th of its starting values and is calculated by dividing the sum of exhaled tidal breaths (cumulative exhaled volume (CEV)) by simultaneously measured functional residual capacity (FRC). An LCI of 7.5 and below is normal; values greater than 7.5 are abnormal. LCI is able to detect abnormalities in lung function earlier than more traditional modalities such as spirometry.

    Time frame: From Baseline up to Week 192

  9. Absolute Change in Weight

    Time frame: From Baseline up to Week 192

  10. Absolute Change in Weight-for-age Z-score

    The z-score is a statistical measure to describe whether a mean was above or below the standard. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean.

    Time frame: From Baseline up to Week 192

  11. Absolute Change in Height

    Time frame: From Baseline up to Week 192

  12. Absolute Change in Height-for-age Z-score

    The z-score is a statistical measure to describe whether a mean was above or below the standard. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean.

    Time frame: From Baseline up to Week 192

07

Results

Posted May 18, 2025

Participant flow

The study was conducted in two parts, Part A and Part B. Participants of both Parts A and B received the same treatment (ELX,TEZ,IVA). Therefore, results data were planned to be collected and analyzed for the overall population of the study and not for separate parts.

Participant flow — Overall Study
MilestoneELX/TEZ/IVAAdditional Participants for Cumulative Triple Combination (TC) Efficacy Set
Started642
Part a completed600
Rollover to part b480
Cumulative tc efficacy set 106/107642
Completed390
Not completed252
Withdrew: Participants did not rollover to part b120
Withdrew: Withdrawal of consent (not due to ae)60
Withdrew: Commercial drug is available for participant60
Withdrew: Adverse event10
Withdrew: Not enrolled in 107 study02

Outcome measures

PrimarySafety and Tolerability as Assessed by Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame:
From Baseline up to Week 196
Reported as:
Count of participants · Participants
Safety and Tolerability as Assessed by Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
ParticipantsELX/TEZ/IVA
Participants with TEAEs64
Participants with SAEs7
SecondaryAbsolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

Time frame:
From Baseline up to Week 192
Reported as:
Least squares mean · percent predicted FEV1
Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)
percent predicted FEV1ELX/TEZ/IVA
Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)9.6 (5.4 to 13.7)
SecondaryAbsolute Change in Sweat Chloride (SwCl)

Sweat samples were collected using an approved collection device.

Time frame:
From Baseline up to Week 192
Reported as:
Least squares mean · millimole per liter (mmol/L)
Absolute Change in Sweat Chloride (SwCl)
millimole per liter (mmol/L)ELX/TEZ/IVA
Absolute Change in Sweat Chloride (SwCl)-57.9 (-63.3 to -52.5)
SecondaryAbsolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score

The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.

Time frame:
From Baseline up to Week 192
Reported as:
Least squares mean · units on a scale
Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score
units on a scaleELX/TEZ/IVA
Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score10.0 (6.9 to 13.0)
SecondaryAbsolute Change in Body Mass Index (BMI)

BMI was defined as weight in kg divided by squared height in meters (m\^2).

Time frame:
From Baseline up to Week 192
Reported as:
Least squares mean · kg/m^2
Absolute Change in Body Mass Index (BMI)
kg/m^2ELX/TEZ/IVA
Absolute Change in Body Mass Index (BMI)3.60 (2.98 to 4.23)
SecondaryAbsolute Change in BMI-for-age Z-score

BMI was defined as weight in kg divided by squared height in meters (m\^2). The z-score is a statistical measure to describe whether a mean was above or below the standard. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean.

Time frame:
From Baseline up to Week 192
Reported as:
Least squares mean · z-score
Absolute Change in BMI-for-age Z-score
z-scoreELX/TEZ/IVA
Absolute Change in BMI-for-age Z-score0.39 (0.19 to 0.59)
SecondaryNumber of Participants With Pulmonary Exacerbations (PEx) for 106/107

Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms.

Time frame:
From Baseline up to Week 192
Reported as:
Count of participants · Participants
Number of Participants With Pulmonary Exacerbations (PEx) for 106/107
ParticipantsELX/TEZ/IVA
Number of Participants With Pulmonary Exacerbations (PEx) for 106/1079
SecondaryNumber of CF-related Hospitalizations for 106/107

The total number of CF related hospitalization (Planned + Unplanned) events across all participants were reported.

Time frame:
From Baseline up to Week 192
Reported as:
Number · hospitalizations
Number of CF-related Hospitalizations for 106/107
hospitalizationsELX/TEZ/IVA
Number of CF-related Hospitalizations for 106/1075
SecondaryAbsolute Change in Lung Clearance Index 2.5 (LCI 2.5)

The LCI2.5 index is the number of lung turnovers required to reduce the end tidal inert gas concentration to 1/40th of its starting values and is calculated by dividing the sum of exhaled tidal breaths (cumulative exhaled volume (CEV)) by simultaneously measured functional residual capacity (FRC). An LCI of 7.5 and below is normal; values greater than 7.5 are abnormal. LCI is able to detect abnormalities in lung function earlier than more traditional modalities such as spirometry.

Time frame:
From Baseline up to Week 192
Reported as:
Least squares mean · index
Absolute Change in Lung Clearance Index 2.5 (LCI 2.5)
indexELX/TEZ/IVA
Absolute Change in Lung Clearance Index 2.5 (LCI 2.5)-2.33 (-2.87 to -1.79)
SecondaryAbsolute Change in Weight
Time frame:
From Baseline up to Week 192
Reported as:
Least squares mean · Kilogram (kg)
Absolute Change in Weight
Kilogram (kg)ELX/TEZ/IVA
Absolute Change in Weight19.9 (18.1 to 21.7)
SecondaryAbsolute Change in Weight-for-age Z-score

The z-score is a statistical measure to describe whether a mean was above or below the standard. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean.

Time frame:
From Baseline up to Week 192
Reported as:
Least squares mean · z-score
Absolute Change in Weight-for-age Z-score
z-scoreELX/TEZ/IVA
Absolute Change in Weight-for-age Z-score0.38 (0.20 to 0.55)
SecondaryAbsolute Change in Height
Time frame:
From Baseline up to Week 192
Reported as:
Least squares mean · centimeters (cm)
Absolute Change in Height
centimeters (cm)ELX/TEZ/IVA
Absolute Change in Height23.1 (21.6 to 24.6)
SecondaryAbsolute Change in Height-for-age Z-score

The z-score is a statistical measure to describe whether a mean was above or below the standard. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean.

Time frame:
From Baseline up to Week 192
Reported as:
Least squares mean · z-score
Absolute Change in Height-for-age Z-score
z-scoreELX/TEZ/IVA
Absolute Change in Height-for-age Z-score0.04 (-0.12 to 0.19)

Adverse events

Collected over Day 1 Up to Week 196. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ELX/TEZ/IVA0/64 (0%)7/64 (10.9%)62/64 (96.9%)
Most frequent serious events
Most frequent serious events
EventELX/TEZ/IVA
ConstipationGastrointestinal disorders3/64
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations2/64
PyrexiaGeneral disorders1/64
Anaphylactic reactionImmune system disorders1/64
Haematuria traumaticInjury, poisoning and procedural complications1/64
Idiopathic intracranial hypertensionNervous system disorders1/64
Most frequent other events
Showing 10 of 32
Most frequent other events
EventELX/TEZ/IVA
CoughRespiratory, thoracic and mediastinal disorders40/64
PyrexiaGeneral disorders28/64
HeadacheNervous system disorders26/64
Oropharyngeal painRespiratory, thoracic and mediastinal disorders24/64
Nasal congestionRespiratory, thoracic and mediastinal disorders23/64
RhinorrhoeaRespiratory, thoracic and mediastinal disorders21/64
Upper respiratory tract infectionInfections and infestations19/64
COVID-19Infections and infestations18/64
VomitingGastrointestinal disorders17/64
Abdominal painGastrointestinal disorders14/64

Baseline characteristics

All participants who received at least one dose of the study drug in this OLE study were included in the baseline characteristics.

Age, Continuous
Age, Continuous(years)ELX/TEZ/IVA
Mean9.3 ± 1.8
Sex: Female, Male
Sex: Female, Male(Participants)ELX/TEZ/IVA
Female39
Male25
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)ELX/TEZ/IVA
Hispanic or Latino0
Not Hispanic or Latino56
Not collected per local regulations8
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)ELX/TEZ/IVA
White55
Asian0
Not collected per local regulations8
More than one Race1
08

Study locations

21 sites
  • Children's Hospital of Orange County
    Orange, California 92868, United States
  • Children's Hospital Colorado
    Aurora, Colorado 80045, United States
  • Ann & Robert Lurie Children's Hospital of Chicago
    Chicago, Illinois 60611, United States
  • Boston Children's Hospital
    Boston, Massachusetts 02115, United States
  • Children's Respiratory and Critical Care Specialists, P.A., Children's Hospitals and Clinics of Minnesota
    Minneapolis, Minnesota 55404, United States
  • The Children's Mercy Hospital
    Kansas City, Missouri 64108, United States
  • Northwell Health- Long Island Jewish Medical Center
    New Hyde Park, New York 11040, United States
  • Clinical Research of Charlotte
    Charlotte, North Carolina 28277, United States
  • Rainbow Babies and Children's Hospital/University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106, United States
  • Nationwide Children's Hospital
    Columbus, Ohio 43205, United States
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
  • Texas Children's Hospital
    Houston, Texas 77030, United States
  • Seattle Children's Hospital
    Seattle, Washington 98105, United States
  • Queensland Children's Hospital
    South Brisbane, Australia
  • The Children's Hospital at Westmead
    Westmead, Australia
  • The Hospital for Sick Children
    Toronto, Canada
  • British Columbia's Children's Hospital
    Vancouver, Canada
  • Children's Health Ireland at Crumlin
    Dublin, Ireland
  • Children's Health Ireland at Temple Street
    Dublin, Ireland
  • Birmingham Children's Hospital - NHS Foundation Trust
    Birmingham, United Kingdom
  • Royal Brompton & Harefield NHS Foundation Trust, Royal Brompton Hospital
    London, United Kingdom
09

References and documents

Publications

  • Southern KW, Murphy J, Sinha IP, Nevitt SJ. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del). Cochrane Database Syst Rev. 2020 Dec 17;12(12):CD010966. doi: 10.1002/14651858.CD010966.pub3. PubMed 33331662 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent research/clinical-trial-data-sharing

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2020 to primary completion in Feb 2024, 48 months.

Results were first posted in May 2025, 1 year 2 months after primary completion.

Of 58 industry-sponsored phase 3 interventional studies under Cystic Fibrosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's 48 months is above that.

Counting every sponsor, half of 67 studies reached it within 26 months; a quarter within 16 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 28, 2019
First posted
Dec 3, 2019
StartActual
Feb 17, 2020
Primary completionActual
Feb 24, 2024
CompletionActual
Feb 24, 2024
Results first posted
May 18, 2025
Last update
May 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04183790
Responsible party
Sponsor
First posted
Dec 3, 2019
Start date
Feb 17, 2020
Primary completion
Feb 24, 2024
Completion
Feb 24, 2024
Results posted
May 18, 2025
Last update
May 18, 2025

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Elexacaftor · Tezacaftor · Ivacaftor

Start the discussion